ClinicalTrials.gg
RecruitingNCT06360900CONVERGEUpdated Nov 18, 2026

Synergistic Gut-brain Axis Modulation Via Vagal Stimulation and Support Therapy in Functional Dyspepsia

An interventional study of Sensory device and Skills Building in Functional Dyspepsia, sponsored by Spaulding Rehabilitation Hospital. Recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Spaulding Rehabilitation Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year later.
Updated Nov 18, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 77 studies in Dyspepsia with a site in United States — 14 open to participants now, 18 under way, 1 of them phase 3. Dyspepsia · United States.

Planned enrollment
21st of 67
80 · median 50
Started
2025
with 3 others
No phase
34 of 77
10 open now
Primary completion
2030-03
later than 16 of 17 live
Registered
70th of 77
by date

Among the 77 studies in Dyspepsia with a site in United States, this one is the 21st largest by planned enrollment of the 67 interventional ones that give a count, is one of 4 that started in 2025, is one of 34 with no phase, reaches primary completion later than 16 of the 17 other live ones, and was the 70th registered.

Dyspepsia

373 studies on the registry are indexed under Dyspepsia; 67 are open to participants now.

Browse Dyspepsia studies →

Open to participants now

14 of the 77 studies in Dyspepsia with a site in United States are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 46 Dyspepsia studies recruiting now, 16 (35%) set no upper age limit and 23 (50%) stop at 75 or younger; 2 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 77 studies in Dyspepsia with a site in United States, or all of them as a file.
02

Study summary

The study aims at evaluating physiological and patient-reported outcomes for a dual intervention approach including a stimulation device and support therapy in patients with functional dyspepsia.

03

Conditions studied

  • Functional Dyspepsia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Age 18-65 years old (inclusive)

  • Ability to give written consent and participate in behavioral intervention in English
  • Willingness to attend weekly treatment sessions over live video, daily self-administered transcutaneous auricular vagus nerve stimulation (taVNS) sessions, and engage in homework during treatment
  • Avoidance of alcohol, nicotine, and caffeine for 24 hours prior to study session
  • Diagnosis according to the Rome IV criteria for both epigastric pain syndrome and postprandial distress syndrome subtypes
  • Stable medical treatment for functional dyspepsia (FD) during 1 month before the study and during the study period

Exclusion criteria

Exclusion Criteria:

  • Previous receipt of cognitive behavioral therapy (CBT) for gastrointestinal symptoms
  • Enteral or parenteral feeding
  • Previous gastrointestinal surgery, electrolyte disturbances, kidney dysfunction, renal insufficiency, or iron overload disorders
  • Estimated (eGFR) \< 60
  • Medications that affect gastrointestinal motility in addition to medications or products containing tetrahydrocannabinol (THC) will be stopped at least 7 days prior to the start of the study and for the duration of the study. However, anti-depressants (SSRI's, TCA's) may be allowed in order to reduce the risk of worsening neuropsychiatric disease, though it will be up to the study team and the Principal Investigator whether subjects on anti-depressants will be able to participate in the study
  • Intellectual disability by history
  • Diabetes, mitochondrial disease, severe autonomic dysfunction, and small fiber polyneuropathy
  • No active clinical acupuncture therapy
  • Illicit drugs or opioid usage
  • History of arrhythmias
  • Current pregnancy/breastfeeding
  • for magnetic resonance imaging (MRI) (implanted ferromagnetic objects, claustrophobia)
  • Weight > 450 lbs. (limit of the MRI table)
  • Allergy to pineapple (used in the test meal during MRI)
  • Any other condition interfering with study requirements, according to the Investigator
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Sensory device + Skills Building

    Device: Sensory device · Behavioral: Skills Building

  • Active comparator
    Sensory device + Health Education

    Device: Sensory device · Behavioral: Health Education

  • Active comparator
    Subsensory device + Skills Building

    Behavioral: Skills Building · Device: Subsensory device

  • Sham comparator
    Subsensory device + Health Education

    Behavioral: Health Education · Device: Subsensory device

Interventions

  • DeviceSensory device

    Sensory vagal nerve stimulation

  • BehavioralSkills Building

    Skills Building behavioral therapy

  • BehavioralHealth Education

    Education of FD condition

  • DeviceSubsensory device

    Subsensory vagal nerve stimulation

06

What researchers measure

Primary outcomes

  1. Visceral Sensitivity Index (VSI)

    GI-related anxiety; score ranging from score ranging from 0 to 75, with higher scores indicating worse outcomes

    Time frame: 8 weeks (post-treatment)

Secondary outcomes

  1. Gastric peristaltic velocity

    MRI-derived gastric motility outcome

    Time frame: 8 weeks (post-treatment)

  2. Nepean Dyspepsia Index (NDI)

    FD symptoms severity; score ranging from 0 to 100, with higher scores indicating worse outcomes

    Time frame: 8 weeks (post-treatment)

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Mar 2030, 53 months after the start.

Of 71 non-industry interventional studies with no phase under Dyspepsia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 28. This study's planned 53 months is above that.

Counting every sponsor, half of 79 studies reached it within 17 months; a quarter within 9 and three quarters within 34.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 18, 2026: primary completion Mar 2029 → Mar 2030 and completion Mar 2029 → Mar 2030.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 3, 2024
First posted
Apr 11, 2024
StartActual
Oct 29, 2025
Primary completionEst.
Mar 2030was Mar 2029
CompletionEst.
Mar 2030was Mar 2029
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Mar 2029→Mar 2030
Nov 18, 2026
Study completion
Mar 2029→Mar 2030
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Primary completion Mar 2029→Mar 2030
    Study completion Mar 2029→Mar 2030
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06360900
Responsible party
Roberta Sclocco (Assistant Professor, Spaulding Rehabilitation Hospital) — Principal investigator
First posted
Apr 11, 2024
Start date
Oct 29, 2025
Primary completion
Mar 2030 (estimated)
Completion
Mar 2030 (estimated)
Last update
Nov 18, 2026

Study contacts

Luca McKerley Coronado
Contact
convergestudy@mgb.org
857-238-0962

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion